BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17867600)

  • 1. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
    Grote HJ
    Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
    Schmiemann V; Böcking A; Kazimirek M; Onofre AS; Gabbert HE; Kappes R; Gerharz CD; Grote HJ
    Clin Cancer Res; 2005 Nov; 11(21):7728-34. PubMed ID: 16278393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
    Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
    Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Rohr UP; Kappes R; Gabbert HE; Böcking A
    Int J Cancer; 2005 Sep; 116(5):720-5. PubMed ID: 15849750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
    Ilse P; Biesterfeld S; Pomjanski N; Wrobel C; Schramm M
    Cancer Genomics Proteomics; 2014; 11(5):251-8. PubMed ID: 25331797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
    Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
    Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
    J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
    Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
    BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypermethylation of p16 gene in clinical specimens of patients with lung cancer].
    Liu JY; An Q; Xu GD; Lei WD; Li L; Pan QJ; Han NJ; Cheng SJ; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):75-7. PubMed ID: 15059321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer.
    Usadel H; Brabender J; Danenberg KD; Jerónimo C; Harden S; Engles J; Danenberg PV; Yang S; Sidransky D
    Cancer Res; 2002 Jan; 62(2):371-5. PubMed ID: 11809682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3.
    Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y
    Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.
    Tan S; Sun C; Wei X; Li Y; Wu Y; Yan Z; Feng F; Wang J; Wu Y
    Exp Lung Res; 2013; 39(4-5):182-90. PubMed ID: 23614702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
    Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
    J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraoperative molecular margin analysis in head and neck cancer.
    Goldenberg D; Harden S; Masayesva BG; Ha P; Benoit N; Westra WH; Koch WM; Sidransky D; Califano JA
    Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):39-44. PubMed ID: 14732766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.